Facebook
Twitter
LinkedIn
Forward
Virtual Symposium - Optimizing Postprandial Glucose Control in Patients with Diabetes: Clinical Advances and Strategies
Current evidence supports post-prandial glucose (PPG) control as an important strategy to consider in the comprehensive management plan of individuals with diabetes. However, managing PPG remains one of the most challenging aspects of diabetes care.
One of the key steps to PPG control is the addition of prandial insulins, and the advent of faster-acting prandial insulins, together with improved continuous glucose monitoring (CGM) and insulin delivery systems, has given clinicians additional options to improve PPG management for people with insulin-treated diabetes. Clinicians should keep up-to-date on these advances so that they can effectively integrate and apply them to improve outcomes in their patients. During this symposium, expert faculty will discuss practical approaches to improving PPG, including insulin dosing, lifestyle approaches, and the utilization of CGM in this setting.
Target Audience
This activity is designed for US-based healthcare professionals, including primary care clinicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, cardiologists, lipidologists, and other allied health professionals.
Learning Objectives
After completing this activity, the participant should be better able to:
- Identify practical dietary and lifestyle modifications as adjunct therapy in minimizing PPG excursions in insulin-treated patients
- Outline the efficacy, safety, and appropriate use of faster acting insulins in the management of PPG
- Summarize the different CGM platforms and their utility in optimizing PPG control
- Develop individualized treatment plans to optimize PPG control in patients with diabetes, including the use of newer generation prandial insulins and CGM
Anne L. Peters, MD (Chair)
Professor, Keck School of Medicine
Director, Clinical Diabetes Programs
University of Southern California
Los Angeles, CA
Dr. Peters discloses the following:
Participation on an advisory board for: Abbott Diabetes Care, Boehringer Ingelheim, Eli Lilly and Company, Livongo, MannKind, Merck, Novo Nordisk, Sanofi, Pendulum Therapeutics
Research Support: Dexcom, vTvTherapeutics, and donated devices from Abbott Diabetes Care
Speaker’s Bureau: Novo Nordisk
Stock Options: Mellitus Health, Omada Health, Stability Health, Pendulum Therapeutics, Livongo
Irl B. Hirsch, MD
Professor of Medicine
Diabetes Treatment and Teaching Chair
University of Washington Medical Center
Medical Director
UWMC Diabetes Care Center
Seattle, WA
Dr. Hirsch discloses:
Consulting Fees: Abbott, BigFoot
Contracted Research: Medtronic, Insulet
Athena Philis-Tsimikas, MD
Corporate Vice President
Scripps Whittier Diabetes Institute
San Diego, CA
Dr. Philis-Tsimikas discloses the following:
Salary (Spouse): Ionis
Contracted Research: Dexcom, Lilly, Novo, Sanofi
ESTIMATED TIME TO COMPLETE ACTIVITY
1.0 hour
EDUCATIONAL GRANT SUPPORT
Multisupported by educational grants from Medtronic and Dexcom, Inc.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.
CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education.
This is a knowledged-based activity. Universal Activity Numbers (UAN): #JA4008162-9999-21-2493-H01-P
For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.
CONTINUING DIETICIAN EDUCATION
This program offers 1.0 CPEUs for dieticians.
ABIM MOC CERTIFICATION
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) maintenance of certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The PIM planners and managers have nothing to disclose. The CMHC planners and managers have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
During the period March 31, 2021 through March 31, 2022, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.
For questions about the accreditation of this activity, please visit www.pimed.com.
For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.
Available Credit
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 CDE
- 1.00 Participation
Required Hardware/software
This online activity must be viewed with the latest version of Chrome, Firefox or Internet Explorer. If you do not have these browsers, you can download Chrome here, Firefox here and Internet Explorer here. Optimal viewing requires a broadband connection of at least 3 Mbps and a 1 GHz processor with 1 GB RAM.